详细指南即将推出
我们正在为PCOS Diagnostic Criteria编写全面的教育指南。请尽快回来查看逐步解释、公式、真实案例和专家提示。
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting approximately 8-13% of women globally depending on the diagnostic criteria applied. It is characterised by a combination of reproductive, metabolic, and psychological features driven by androgen excess and insulin resistance. The Rotterdam criteria (2003), the most widely used diagnostic framework, require the presence of at least two of three features: oligomenorrhoea or anovulation (irregular or absent periods, typically fewer than nine cycles per year); clinical or biochemical hyperandrogenism (excess androgens causing hirsutism, acne, and alopecia, or elevated serum androgens including total testosterone, free testosterone, or DHEAS); and polycystic ovarian morphology on ultrasound (12 or more follicles 2-9 mm in diameter per ovary, and/or ovarian volume above 10 mL). The more stringent NIH 1990 criteria require both oligo/anovulation and clinical or biochemical hyperandrogenism, excluding the ultrasound criterion. The Androgen Excess Society criteria require hyperandrogenism as a mandatory feature. HOMA-IR is frequently elevated in PCOS due to underlying insulin resistance, which drives compensatory hyperinsulinaemia, further stimulating androgen production from the ovarian theca cells. The long-term metabolic consequences of PCOS include a substantially increased risk of type 2 diabetes (7-10 fold), metabolic syndrome, endometrial cancer, and cardiovascular disease. Psychological burden including depression, anxiety, and body image disturbance is also significant. PCOS is a diagnosis of exclusion — other causes of hyperandrogenism and oligomenorrhoea (thyroid disease, hyperprolactinaemia, congenital adrenal hyperplasia, androgen-secreting tumours) must be excluded.
Rotterdam Criteria (2003): Diagnosis requires 2 of 3: (1) Oligo/anovulation, (2) Clinical or biochemical hyperandrogenism, (3) Polycystic ovaries on USS (≥12 follicles 2-9mm per ovary or volume >10mL). Other causes must be excluded.
- 1Take a detailed menstrual history: cycle length, regularity, and any periods of amenorrhoea. Oligomenorrhoea is defined as fewer than nine cycles per year or cycles longer than 35 days.
- 2Assess clinical hyperandrogenism: modified Ferriman-Gallwey score for hirsutism (above 4-6 is clinically significant in European women; lower thresholds for Asian women); presence of acne, androgenic alopecia.
- 3Measure biochemical androgens: total testosterone, SHBG (to calculate free androgen index or free testosterone), and DHEAS. Elevated free testosterone with low SHBG (from insulin resistance) is common.
- 4Arrange transvaginal or transabdominal pelvic ultrasound: assess follicle count per ovary (FNPO), follicle size, and ovarian volume. Transabdominal USS is appropriate for sexually inactive women.
- 5Exclude other diagnoses: measure TSH (thyroid disease), prolactin (hyperprolactinaemia), 17-OH progesterone (non-classic CAH), and DHEAS (if very high, consider adrenal tumour).
- 6Apply the Rotterdam criteria: any two of three features after excluding other diagnoses confirms PCOS.
- 7Assess metabolic risk: measure fasting glucose, HOMA-IR, lipid profile, BMI, and waist circumference — these inform cardiometabolic risk stratification and treatment decisions.
Metabolic workup required; weight management and lifestyle intervention first-line
This woman fulfils all three Rotterdam criteria — irregular cycles, hyperandrogenism (both clinical and biochemical), and polycystic ovarian morphology. Assessment for insulin resistance and metabolic syndrome is essential. Combined oral contraceptive pill addresses menstrual irregularity and hirsutism; metformin or inositol addresses insulin resistance.
NIH criteria are more stringent and identify the most androgenic phenotype
This patient meets NIH PCOS criteria because she has both oligoanovulation and biochemical hyperandrogenism. She does not meet Rotterdam criteria for polycystic ovarian morphology on USS (under 12 follicles per ovary, volume under 10 mL). NIH criteria identify the classic high-androgen phenotype, which has the greatest long-term metabolic risk.
Lean PCOS phenotype — may have preserved metabolic profile but reproductive risks remain
Lean PCOS (non-obese phenotype) is less common than obese PCOS but equally valid diagnostically. Insulin resistance may be less severe, HOMA-IR may be normal, and metabolic risk is lower, but ovarian dysfunction and androgen excess still require management. Spironolactone for hirsutism, lifestyle monitoring are appropriate.
Metformin, weight management, and aggressive cardiometabolic risk reduction essential
This woman has PCOS combined with metabolic syndrome — the highest-risk PCOS phenotype. HOMA-IR of 5.8 indicates severe insulin resistance. The 10-year risk of type 2 diabetes is substantially elevated. Metformin, dietary intervention, GLP-1 receptor agonist for weight management, and regular monitoring for diabetes development are all indicated.
Guiding the investigation and diagnosis of women presenting with irregular periods, hirsutism, or acne in primary care and gynaecology, representing an important application area for the Pcos Risk in professional and analytical contexts where accurate pcos risk calculations directly support informed decision-making, strategic planning, and performance optimization
Assessing fertility prognosis and selecting ovulation induction strategies in women with PCOS-related infertility, representing an important application area for the Pcos Risk in professional and analytical contexts where accurate pcos risk calculations directly support informed decision-making, strategic planning, and performance optimization
Stratifying long-term metabolic and cardiovascular risk to guide intensity of metabolic monitoring and intervention, representing an important application area for the Pcos Risk in professional and analytical contexts where accurate pcos risk calculations directly support informed decision-making, strategic planning, and performance optimization
Selecting contraceptive methods that simultaneously manage androgenic symptoms (COCP) or protect the endometrium (progesterone-releasing IUS), representing an important application area for the Pcos Risk in professional and analytical contexts where accurate pcos risk calculations directly support informed decision-making, strategic planning, and performance optimization
Identifying insulin resistance in PCOS to guide pharmacological intervention with metformin, inositol, or GLP-1 receptor agonists, representing an important application area for the Pcos Risk in professional and analytical contexts where accurate pcos risk calculations directly support informed decision-making, strategic planning, and performance optimization
Adolescent PCOS
{'title': 'Adolescent PCOS', 'body': "Diagnosing PCOS in adolescents is challenging because oligomenorrhoea and polycystic ovarian morphology are common within 2 years of menarche as part of normal pubertal maturation. Irregular cycles in adolescents should only raise PCOS concern if persisting beyond 2-3 years post-menarche. A diagnosis of 'at-risk for PCOS' with monitoring is often preferred over definitive PCOS diagnosis in teenagers."}
PCOS in women with type 1 diabetes
{'title': 'PCOS in women with type 1 diabetes', 'body': 'Women with type 1 diabetes who are hyperinsulinaemic from exogenous insulin can develop PCOS-like features. The prevalence of PCOS in type 1 diabetes is approximately 40% — substantially higher than the general population. Differentiating hyperinsulinaemia-driven ovarian dysfunction from classic PCOS requires careful assessment of the insulin dose, glycaemic control, and ovarian function.'}
PCOS and non-classic congenital adrenal hyperplasia (NCCAH)
{'title': 'PCOS and non-classic congenital adrenal hyperplasia (NCCAH)', 'body': 'Non-classic CAH (21-hydroxylase deficiency) can mimic PCOS exactly, presenting with oligomenorrhoea, hyperandrogenism, and polycystic ovarian morphology. The prevalence of NCCAH is approximately 4% in women presenting with PCOS features. 17-OH progesterone measurement (ideally stimulated with Synacthen) should be performed to exclude NCCAH before diagnosing PCOS.'}
Pregnancy complications in PCOS
{'title': 'Pregnancy complications in PCOS', 'body': 'PCOS is associated with increased rates of gestational diabetes mellitus, pregnancy-induced hypertension, pre-eclampsia, preterm birth, and pregnancy loss. Women with PCOS who conceive should be screened early for gestational diabetes (from the first trimester if insulin-resistant), monitored for hypertension, and considered for low-dose aspirin to reduce pre-eclampsia risk.'}
| Criteria | Year | Required Features | Key Distinction |
|---|---|---|---|
| NIH | 1990 | Both: anovulation + hyperandrogenism | Strictest; excludes USS criterion |
| Rotterdam | 2003 | 2 of 3: anovulation, hyperandrogenism, polycystic ovaries | Most inclusive; most widely used |
| AES | 2006 | Hyperandrogenism mandatory + either anovulation or polycystic ovaries | Hyperandrogenism is non-negotiable |
| Endocrine Society | 2013 | Menstrual + androgen criteria; USS optional | Favours NIH-style clinical approach |
Can a woman have PCOS without polycystic ovaries on scan?
Yes. Under Rotterdam criteria, polycystic ovarian morphology on USS is only one of three criteria. A woman with oligoanovulation plus hyperandrogenism meets Rotterdam criteria for PCOS without a USS finding of polycystic ovaries. The name 'polycystic ovary syndrome' is somewhat misleading — the diagnosis does not require polycystic ovaries. This is particularly important in the context of pcos risk calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise pcos risk computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
Is PCOS hereditary?
PCOS has a strong hereditary component — approximately 50% of first-degree female relatives of women with PCOS have features of the condition. Multiple genes contributing to androgen metabolism, insulin signalling, and gonadotrophin regulation have been implicated. The inheritance pattern is complex polygenic rather than simple Mendelian. This is particularly important in the context of pcos risk calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise pcos risk computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
Does PCOS cause infertility?
PCOS is the most common cause of anovulatory infertility, accounting for approximately 70% of anovulatory infertility cases. Irregular or absent ovulation means eggs are not released regularly, reducing fertility. However, most women with PCOS can achieve pregnancy with appropriate treatment including weight loss, ovulation induction (clomiphene, letrozole), or IVF if needed.
Does PCOS resolve after menopause?
The reproductive features of PCOS (irregular periods, ovarian morphology changes) naturally resolve after menopause when ovarian function ceases. However, the underlying metabolic consequences — insulin resistance, elevated cardiovascular risk, and associated metabolic syndrome — persist. Post-menopausal women with prior PCOS have higher rates of type 2 diabetes, hypertension, and cardiovascular disease.
What is the first-line treatment for PCOS?
Lifestyle modification — particularly weight loss in overweight and obese women — is the cornerstone of PCOS management. A 5-10% reduction in body weight restores menstrual regularity in 50-60% of women, reduces hyperandrogenism, and improves metabolic parameters. For menstrual regulation and contraception, combined oral contraceptive pills are effective. Metformin or inositol is used for insulin resistance. Letrozole is preferred over clomiphene for ovulation induction.
Does the combined oral contraceptive pill treat PCOS?
The COCP manages the symptoms of PCOS (irregular periods, hyperandrogenism-related symptoms) but does not treat the underlying pathophysiology. On stopping the COCP, menstrual irregularity and androgen excess typically return. The COCP suppresses ovarian androgen production and raises SHBG, reducing free testosterone, which improves acne and hirsutism. It does not address insulin resistance.
What role does inositol play in PCOS treatment?
Myo-inositol and D-chiro-inositol are naturally occurring isomers involved in insulin signal transduction. Supplementation (typically 2-4g myo-inositol daily) has been shown in multiple RCTs to reduce insulin resistance, improve menstrual regularity, reduce androgen levels, and improve oocyte quality in women with PCOS. It is generally well tolerated and considered a complementary approach alongside lifestyle modification.
What is the endometrial cancer risk in PCOS?
Women with PCOS have approximately 2-3 times the risk of endometrial cancer compared with unaffected women. The mechanism is prolonged unopposed oestrogen exposure from anovulatory cycles (no progesterone from corpus luteum formation). Women with infrequent or absent periods (fewer than four per year) should be assessed for endometrial hyperplasia, and progesterone (oral or intrauterine) is used to protect the endometrium.
专业提示
Measure free testosterone (calculated from total T and SHBG) rather than relying on total testosterone alone in women suspected of PCOS. Insulin resistance lowers SHBG, amplifying the proportion of testosterone that is free and biologically active — total testosterone may be in the 'normal' female range while free testosterone is clearly elevated.
你知道吗？
PCOS was first described in 1935 by American gynaecologists Irving Freiler Stein and Michael Leo Leventhal, who noted the association between polycystic ovaries and amenorrhoea, hirsutism, and obesity. For decades it was called the Stein-Leventhal syndrome. The modern understanding of its metabolic and hormonal complexity — particularly the role of insulin resistance — was not established until the 1980s.
参考资料
- ›Rotterdam ESHRE/ASRM PCOS Consensus Workshop Group 2003. Revised 2003 consensus on diagnostic criteria for PCOS. Human Reproduction 2004
- ›Teede HJ et al. International Evidence-Based Guideline for the Assessment and Management of PCOS 2018
- ›Legro RS et al. Diagnosis and Treatment of PCOS: An Endocrine Society Clinical Practice Guideline 2013
- ›NICE CG156 — Fertility Problems: Assessment and Treatment 2013 (updated 2023)